20 articles
A first-of-its-kind trial shows therapeutic plasma exchange plus IVIG reduced biological age by an average of 2.6 years, confirmed by multi-omics analysis.
A quality improvement study found dialysis patients receiving liquid protein supplements had fewer, shorter hospital stays and better nutritional biomarkers.
Tzield becomes the first FDA-approved disease-modifying therapy for recently diagnosed Stage 3 type 1 diabetes in pediatric patients ages 8–17.
A low-dose three-drug pill slashed recurrent stroke risk and improved blood pressure control in intracerebral hemorrhage survivors, a major RCT found.
A randomized trial found hypothermic oxygenated perfusion slashed early graft failure rates from 37% to 20% in liver transplant patients.
A transdermal patch delivering PAH drug treprostinil via a liver-activated prodrug shows promising Phase 1 safety and delivery results.
Celularity and Fountain Life are offering an investigational cell therapy in Florida under a new state law bypassing FDA approval.
A polypill combining three BP drugs slashed recurrent stroke risk from 7.4% to 4.6% in hemorrhagic stroke survivors, per a New England Journal study.
A novel dual CAR T-cell approach eliminated blocking antibodies in highly sensitized patients, enabling kidney transplants previously considered impossible.
Heartseed's iPSC-derived heart cell therapy enters Phase I/II trial for dilated cardiomyopathy, with first patient data cleared by safety board.
Denali's Avlayah uses a novel transport platform to cross the blood-brain barrier, cutting CSF biomarkers by 91% in trials.
Deramiocel slowed upper limb decline by 54% and preserved heart function in boys with Duchenne muscular dystrophy in a landmark phase III trial.
A phase III trial shows talquetamab combinations dramatically improve survival in relapsed multiple myeloma, with 81% two-year progression-free survival.
The FDA expanded approval of teplizumab to toddlers with preclinical type 1 diabetes, potentially delaying disease onset during critical early years.
Scribe Therapeutics reports a one-time epigenetic therapy slashed LDL cholesterol up to 68% for nearly two years in primates.
Cyclarity's UDP-003 shows first human evidence of excreting oxidized cholesterol, pointing toward reversing arterial damage rather than just slowing it.
VERVE-102 permanently silences the PCSK9 gene in a single dose, slashing LDL cholesterol up to 62% with encouraging early safety data.
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
A pilot trial found tailored DASH coaching plus produce prescriptions slashed systolic BP by 13 mmHg in adherent adults with uncontrolled hypertension.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
